BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 751007)

  • 1. Effect of Venoruton on the factor XIII activity in rat plasma.
    Grochal M; Sempińska-Edelberg E; Plewiński J
    Pol J Pharmacol Pharm; 1978; 30(5):659-63. PubMed ID: 751007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of O-(beta-hydroxyethyl)-rutosides (HR) on the skin capillary resistance of rats.
    Gábor M
    Arzneimittelforschung; 1981; 31(3):442-5. PubMed ID: 7194669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of hydroxyethylrutosides (HR): metabolism of [14C]-HR in man.
    Hackett AM; Griffiths LA; Luyckx AS; van Cauwenberge H
    Arzneimittelforschung; 1976; 26(5):925-8. PubMed ID: 989368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of O-(beta-hydroxyethyl)-rutosides on function and structure of the ganglion cells.
    Blasius W; Leusser K; Merker G
    Arzneimittelforschung; 1976; 26(9):1645-50. PubMed ID: 1036693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dose schedule of vitamin E and hydroxethylruticide on intestinal toxicity induced by adriamycin.
    McGinness JE; Grossie B; Proctor PH; Benjamin RS; Gulati OP; Hokanson JA
    Physiol Chem Phys Med NMR; 1986; 18(1):17-24. PubMed ID: 3774891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticatatonic effect of venoruton.
    Aley KO; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 1988 Apr; 10(4):263-5. PubMed ID: 2898576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O-(beta-hydroxyethyl)-rutoside (Venoruton) fails to block histamine or bradykinin-induced edema formation in the canine forelimb perfused at constant arterial inflow.
    Dobbins DE; Soika CY; Dabney JM
    Microcirc Endothelium Lymphatics; 1984 Oct; 1(5):509-23. PubMed ID: 6546155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. o-(beta-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment.
    Bull JM; Strebel FR; Sunderland BA; Bulger RE; Edwards M; Siddik ZH; Newman RA
    Cancer Res; 1988 Apr; 48(8):2239-44. PubMed ID: 3349489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers.
    Kienzler JL; Sallin D; Schifflers MH; Ghika A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):395-402. PubMed ID: 12242598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and platelet fibrin-stabilizing factor activity in rats intoxicated with phenylmercuric acetate.
    Michalska M; Wierzbicki R
    Pol J Pharmacol Pharm; 1984; 36(6):611-5. PubMed ID: 6535154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of O-(beta-hydroxyethyl)-rutoside (venoruton) on the adherence of leukocytes in patients with arteriosclerosis obliterans of the lower limbs].
    Lukjan H; Szpak A; Bodzenta A; Bielawiec M; Rosc D; Chyzy R
    Pol Arch Med Wewn; 1985 Jun; 73(6):345-50. PubMed ID: 3880372
    [No Abstract]   [Full Text] [Related]  

  • 13. [Venoruton--used not only in venopathies? Symposium on O-(beta-hydroxyethyl)-rutoside (=Venoruton) in vascular diseases].
    ZFA (Stuttgart); 1981 Sep; 57(26):1758-60. PubMed ID: 7303836
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of HR (O-Beta-Hydroxyethylo-Rutoside, Venoruton) on the deformability of erythrocytes in patients with arteriosclerosis obliterans of lower limbs.
    Lukjan H; Rość D; Chyzy R; Bodzenta A; Szpak A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(1):191-6. PubMed ID: 2581865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of O-(beta-hydroxyethyl)-rutoside on wound healing in the rat.
    Wilhelmi G
    Pharmacology; 1979; 19(2):82-5. PubMed ID: 531085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the hematological profile in rat following whole body gamma radiation with and without venoruton pretreatment.
    Kanwar KC; Verma A
    J Environ Pathol Toxicol Oncol; 1992; 11(4):235-9. PubMed ID: 1507075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of O-(beta-hydroxyethyl)-rutosides (HR) against adriamycin-induced toxicity in rats.
    Gulati OP; Nordmann H; Aellig A; Maignan MF; McGinness J
    Arch Int Pharmacodyn Ther; 1985 Feb; 273(2):323-34. PubMed ID: 4004421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Venoruton and capillary permeability].
    Cesarone MR; Laurora G; Gabini M; Errichi BM; Candiani C; Belcaro G
    Minerva Cardioangiol; 1989 May; 37(5):265-8. PubMed ID: 2779806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Capillary resistance raising action of Venoruton. Experimental data on the therapeutic effects of Venoruton].
    Gábor M
    Acta Pharm Hung; 1983 May; 53(3):115-20. PubMed ID: 6880764
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.
    van Acker SA; Voest EE; Beems DB; Madhuizen HT; de Jong J; Bast A; van der Vijgh WJ
    Cancer Res; 1993 Oct; 53(19):4603-7. PubMed ID: 8402634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.